Peptides as a therapeutic modality attract much attention due to their synthetic accessibility,
high degree of specific binding, and the ability to target protein surfaces traditionally …

Highlights•An unprecedented number of peptide therapeutics have recently been
approved.•Clinical pipeline analysis reveals an emphasis on peptides with enhanced …

Introduction: Rapid clearance of drugs from the body results in short therapeutic half-life and
is an integral property of many protein and peptide-based drugs. To maintain the desired …

Rapid advancements in genomics have brought a better understanding of molecular
mechanisms for various pathologies and identified a number of highly attractive target …

Abstract Development of peptide drugs is challenging but also quite rewarding. Five
blockbuster peptide drugs are currently on the market, and six new peptides received first …

Highlights•Non-antibody scaffold drugs are a promising new class of biologics drugs.•The
first candidate scaffolds are now moving into clinical development and practice.•Challenges …

In the last two decades, protein–protein interactions (PPIs) have been used as the main
target for drug development. However, with larger or superficial binding sites, it has been …

Conspectus Cyclic peptides can bind to protein targets with high affinities and selectivities,
which makes them an attractive modality for the development of research reagents and …

Peptides and small protein scaffolds are gaining increasing interest as therapeutics.
Similarly to full-length antibodies, they can bind a target with a high binding affinity and …

Highlights•PPIs that are dominated by a continuous epitope are amenable for inhibition.•A
significant share of PPIs contains such 'hot segments'.•Peptide-based inhibitors are obvious …